Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Avelumab by Merck for Angiosarcoma: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II drugs...
Avelumab by Merck for Cervical Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Avelumab by Merck for Pancreatic Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Colorectal Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to...
Avelumab by Merck for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial...
Avelumab by Merck for Leiomyosarcoma: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs...
Avelumab by Merck for Endometrial Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...
Avelumab by Merck for Osteosarcoma: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs...
Avelumab by Merck for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
Avelumab by Merck for Ureter Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Ureter Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Urethral Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Urethral Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Metastatic Colorectal Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Avelumab by Merck for Small-Cell Lung Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...
Avelumab by Merck for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
Avelumab by Merck for Glioblastoma Multiforme (GBM): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Avelumab by Merck for Malignant Mesothelioma: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II...
Avelumab by Merck for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData,...